Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
15 studies found for:    Alzheimer rosiglitazone
Show Display Options
Rank Status Study
1 Completed Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: rosiglitazone
Sponsor: GlaxoSmithKline
Age: 50 Years to 85 Years   (Adult, Senior)
2 Completed Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone Extended Release 2mg;   Drug: Rosiglitazone Extended Release 8mg;   Other: Placebo;   Other: Donepezil
Sponsor: GlaxoSmithKline
Age: 50 Years to 90 Years   (Adult, Senior)
3 Completed Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone;   Other: Placebo
Sponsor: GlaxoSmithKline
Age: 50 Years to 85 Years   (Adult, Senior)
4 Completed Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone (Extended Release)
Sponsor: GlaxoSmithKline
Age: 50 Years to 90 Years   (Adult, Senior)
5 Terminated Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone XR
Sponsor: GlaxoSmithKline
Age: 51 Years to 91 Years   (Adult, Senior)
6 Completed Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone
Sponsor: GlaxoSmithKline
Age: 50 Years to 90 Years   (Adult, Senior)
7 Terminated Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone XR
Sponsor: GlaxoSmithKline
Age: 51 Years to 91 Years   (Adult, Senior)
8 Terminated Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone XR (extended release) oral tablets;   Drug: Placebo
Sponsor: GlaxoSmithKline
Age: 50 Years to 85 Years   (Adult, Senior)
9 Completed Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone Extended Release 2mg;   Drug: Rosiglitazone Extended Release 8mg;   Other: Placebo;   Other: Donepezil;   Other: Galantamine;   Other: Rivastigmine
Sponsor: GlaxoSmithKline
Age: 50 Years to 90 Years   (Adult, Senior)
10 Completed Insulin, Neurogenetics and Memory in Alzheimer's Disease
Condition: Alzheimer Disease
Intervention: Drug: rosiglitazone
Sponsor: VA Office of Research and Development
Age: 55 Years to 80 Years   (Adult, Senior)
11 Completed PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone XR
Sponsor: GlaxoSmithKline
Age: 18 Years to 55 Years   (Adult)
12 Completed A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.
Condition: Alzheimer's Disease
Intervention: Drug: BRL-049653
Sponsor: GlaxoSmithKline
Age: 18 Years to 55 Years   (Adult)
13 Unknown  Rosiglitazone Effects on Cognition for Adults in Later Life
Condition: Mild Cognitive Impairment
Intervention: Drug: Rosiglitazone
Sponsor/Collaborators: University of Washington;   National Institute on Aging (NIA);   GlaxoSmithKline
Age: 55 Years and older   (Adult, Senior)
14 Withdrawn QTc Study of Rosi XR in Healthy Volunteers
Condition: Alzheimer's Disease
Interventions: Drug: Rosi XR;   Other: Placebo;   Drug: Moxifloxacin
Sponsor: GlaxoSmithKline
Age: 18 Years to 45 Years   (Adult)
15 Completed Drug Interaction Study Between AZD3480 and Cytochrome P450
Conditions: Metabolism;   Alzheimer's Disease
Interventions: Drug: AZD3480;   Drug: Placebo;   Drug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
Sponsor: AstraZeneca
Age: 18 Years to 55 Years   (Adult)

Study has passed its completion date and status has not been verified in more than two years.